Testing a new drug for moderate-to-severe eczema
Part of Skin clinical trials.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with moderate-to-severe eczema that has not improved with topical treatments (like creams or ointments).
- You are generally healthy aside from your eczema, with no serious infections or conditions.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control.
- You have not had cancer in the past 5 years (except for some easily treated skin cancers).
- You do not have active tuberculosis, hepatitis B or C, syphilis, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication (HXN6005) for people with moderate-to-severe eczema that hasn't been controlled by topical treatments. The goal is to see if the drug is safe and effective in reducing eczema symptoms.
This study tests a new cream (CMS-D001) for people with moderate to severe eczema. Participants will receive either the study cream or a placebo (a cream with no active ingredient) to see if it helps reduce symptoms like itching and redness.
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
Hear when a new Health Adult Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.